AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 274: F252-F258, 1998;
0363-6127/98 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lei, J.
Right arrow Articles by Neugarten, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lei, J.
Right arrow Articles by Neugarten, J.
Vol. 274, Issue 2, F252-F258, February 1998

Serum-stimulated alpha 1 type IV collagen gene transcription is mediated by TGF-beta and inhibited by estradiol

Jun Lei1, Sharon Silbiger1, Fuad N. Ziyadeh2, and Joel Neugarten1

1 Nephrology Division, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467; and 2 Penn Center for Molecular Studies of Kidney Diseases, Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia, Pennsylvania 19104

    ABSTRACT
Top
Abstract
Introduction
Methods
Results
Discussion
References

We examined the hypothesis that fetal calf serum (FCS) stimulates murine mesangial cell alpha 1 type IV collagen (COL4A1) gene transcription by increasing autocrine production of transforming growth factor-beta (TGF-beta ) through a platelet-derived growth factor (PDGF)-dependent mechanism. PDGF-stimulated COL4A1 gene transcription was inhibited by neutralizing antibody to TGF-beta (119.3 ± 3.6 vs. 106.0 ± 6.2 relative luciferase units, expressed as a percentage of control untreated cells, P < 0.003). FCS-stimulated gene transcription was inhibited by neutralizing antibody to PDGF (148.3 ± 4.1 vs. 136.7 ± 0.3 relative luciferase units, P < 0.002) and by neutralizing antibody to TGF-beta (148.3 ± 4.1 vs. 127.1 ± 3.4 relative luciferase units, P < 0.036). The inhibitory effect of combined treatment with anti-PDGF and anti-TGF-beta antibody on gene transcription was no greater than that of anti-TGF-beta antibody alone [129.5 ± 0.53 vs. 127.1 ± 3.4 relative luciferase units, P = not significant (NS)]. FCS-stimulated gene transcription was also inhibited by estradiol (10-7 M) (148.4 ± 3.1 vs. 119.4 ± 8.1 relative luciferase units, P < 0.019). In the presence of estradiol, anti-TGF-beta antibody failed to further reduce serum-stimulated gene transcription (119.4 ± 8.1 vs. 115.6 ± 9.8, P = NS), suggesting that estradiol reverses FCS-stimulated COL4A1 gene transcription by antagonizing the actions of TGF-beta . Measurement of type IV collagen synthesis by Western blotting confirmed that the intact gene responded in a manner analogous to the promoter construct.

mesangial cells; sex hormones; estrogen; mesangial matrix; transforming growth factor-beta

    INTRODUCTION
Top
Abstract
Introduction
Methods
Results
Discussion
References

IT HAS BEEN SUGGESTED THAT the stimulatory effect of serum on the synthesis of several mesangial matrix components is mediated by the ability of platelet-derived growth factor (PDGF) present in serum to stimulate cellular synthesis of transforming growth factor-beta (TGF-beta ) (21). Supporting this hypothesis are the observations that PDGF stimulates the synthesis and release of TGF-beta from cultured mesangial cells (4) and that PDGF-stimulated fibronectin and type III collagen synthesis is mediated by enhanced TGF-beta production (27, 38). In addition, we have previously shown that estradiol supresses alpha 1 type IV collagen synthesis by mesangial cells grown in serum-supplemented media and that estradiol reverses the stimulatory effect of TGF-beta on mesangial cell alpha 1 collagen IV (COL4A1) gene transcription (23, 34). These observations led us to hypothesize that fetal calf serum (FCS) stimulates mesangial cells to increase their synthesis of alpha 1 type IV collagen by increasing cellular production of TGF-beta via a PDGF-dependent mechanism and that the ability of estradiol to suppress alpha 1 type IV collagen synthesis by mesangial cells grown in serum-supplemented media may be mediated by antagonism of the actions of TGF-beta .

In the present study, we examined interactions between serum, PDGF, TGF-beta , estradiol, and COL4A1 gene transcription in murine mesangial cells. We found that exogenous PDGF-stimulated gene transcription was inhibited by neutralizing antibody to either PDGF or TGF-beta . Similarly, FCS-stimulated gene transcription was inhibited by neutralizing antibody to PDGF or to TGF-beta . The inhibitory effect of combined treatment with anti-PDGF and anti-TGF-beta antibodies on FCS-stimulated COL4A1 gene transcription was no greater than that of anti-TGF-beta antibody alone. Estradiol also reversed FCS-stimulated collagen gene transcription. The suppressive effects of estradiol and of anti-TGF-beta antibody on FCS-stimulated COL4A1 gene transcription were not additive. Measurement of type IV collagen synthesis by Western blotting confirmed that the intact gene responded in a manner analogous to the promoter construct. These data suggest that FCS stimulates murine mesangial cell COL4A1 gene transcription, in part, by increasing cellular production of TGF-beta through a PDGF-dependent mechanism and that estradiol suppresses type IV collagen gene transcription by cells grown in serum-supplemented media by antagonizing the effects of TGF-beta .

    METHODS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Isolation and characterization of murine mesangial cells. Mesangial cells were isolated from kidneys of 8- to 10-wk-old naive SJL/J (H-2S) mice by differential glomerular sieving (33). The present studies were performed on an immortalized, differentiated murine mesangial cells line transformed with nonreplicating, non-capsid-forming SV40 virus (strain Rh 911). The cells express receptors for angiotensin II and stain positive for Thy-1 antigen, desmin, vimentin, and types I and IV collagens but fail to bind antibody directed against a proximal tubular antigen (41).

Construction of reporter gene plasmids. A plasmid containing portions of the gene encoding murine alpha 1(IV) collagen was linked to luciferase coding sequences to form a reporter construct HB35, as previously described (13). A 2.3-kb Xho I fragment derived from p184 (gift of Dr. P. Killen, Univ. of Michigan) (7, 19) spanning the first three exons, the first two introns and portion of the third intron of the alpha 2(IV) collagen gene, the intergenic bidirectional promoter region, and a portion of the alpha 1(IV) collagen transcription unit was cloned into pBluescript (Stratagene, La Jolla, CA) and was truncated within the third intron of the alpha 2(IV) gene by excising the appropriate fragment with Hind III. The fragment was then ligated into the Hind III site of the luciferase expression plasmid, pSVOAlucD5' (10), and its orientation was determined by restriction mapping (22). An additional 3.2-kb fragment of the first intron of the alpha 1(IV) gene, previously shown to modulate the activity of the alpha 1(IV) promoter (7, 19), corresponding to a BamH I-linked 3.2-kb Xba I fragment of the first intron of alpha 1(IV), was inserted into the BamH I site downstream from the 3' end of the luciferase coding sequences, following partial BamH I digestion (22). Intron fragment orientation and position were confirmed by restriction mapping (22). A figure of the reporter gene construct has been previously been published (13, 22).

Stable transfection. Murine mesangial cells were cotransfected with HB35 and a selection plasmid pSV2-Neo encoding for neomycin resistance (36) at a molar ratio of 10:1, using the CaPO4-DNA precipitation procedure (3). Cells were then grown in selection medium containing Geneticin (G-418). Cells surviving in medium with Geneticin were expanded and reselected with the neomycin analog. Stable transfectants exhibited patterns of growth behavior and protein synthesis similar to the parent cell line (13).

Luciferase assay. Cells were plated in six-well plates and grown in phenol-free, serum-free RPMI 1640. Cells were exposed to varying concentrations of FCS (0, 5, 10, or 20% FCS), recombinant human PDGF (10 ng/ml) (Upstate Biotechnology, Lake Placid, NY), or TGF-beta 1 (2 ng/ml) (R & D Systems, Minneapolis, MN) in the presence and absence of rabbit anti-human PDGF neutralizing antibody (20 µg/ml) (R & D Systems), rabbit anti-human TGF-beta neutralizing antibody (20 µg/ml) (Upstate Biotechnology), or normal rabbit immunoglobulin G (IgG, 20 µg/ml). In other experiments, cells were treated with 20% FCS in the presence or absence of estradiol (10-7 M) ± rabbit anti-human TGF-beta neutralizing antibody (20 µg/ml) (R & D Systems). The estradiol concentration in FCS was 25.38 pg/ml (final concentrations of estradiol: 1.3 pg/ml, 2.5 pg/ml, and 5.1 pg/ml in 5, 10, and 20% FCS, respectively).

Because FCS may artifactually increase cellular protein determinations by contaminating the cell monolayer with serum-derived proteins, cells were extensively washed with phosphate-buffered saline. Cells were then lysed with 100 µl Reporter Lysis Buffer (Promega, Madison, WI) at room temperature for 15 min. Wells were then scraped, and the cell lysate was transferred to a microcentrifuge tube and placed on ice. Tubes were vortexed and microcentrifuged for 2 min at 4°C. The suspension was transferred to a new microcentrifuge tube and stored at -70°C until assayed. Cell extract (20 µl) was mixed with 10 µl of assay reagent [20 mM tricine, 1.07 mM (MgCO3)4Mg(OH)2 · 5H2O, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 µM coenzyme A, 470 µM luciferin, and 530 µM ATP, pH 7.8] at room temperature (all reagents were from Sigma Chemical, St. Louis, MO). Light emission was measured directly at room temperature over a 10-s period in a luminometer (Promega). Blank reactions were determined with equivalent volumes of lysis buffer substituted for cell lysates, and these values were subtracted from experimental values. Luciferase activity was expressed per milligram of cellular protein in the supernatant as determined by the Bio-Rad protein assay (Bio-Rad, Richmond, CA). Relative luciferase units were calculated as percentages of control values, where 100% is the value obtained with control media (serum-free, no added agents).

Western blotting for type IV collagen. Cells were harvested and immediately placed in chilled homogenizing buffer [0.1 M tris(hydroxymethyl)aminomethane (Tris), 0.1 mM phenylmethylsulfonyl fluoride, 5 mM mercaptoethanol, 0.01% sodium azide, pH 7.2] (2 ml buffer/g cellular protein). The cells were homogenized on ice, and the resultant homogenate was centrifuged at 6,000 revolutions per minute (rpm) for 4 min at 4°C. The supernatant was collected and heated at 65°C for 15 min. Protein content was measured in a 0.1-ml aliquot of supernatant (Bio-Rad protein assay). To prepare the samples for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis, 1 ml of 10% trichloroacetic acid was added to 4 mg/ml of supernatant, and the final volume was brought to 2 ml with distilled water. The sample was vortexed and then centrifuged at 2,000 rpm for 10 min. The pellet was dissolved in 1 ml of loading buffer (2% SDS, 10% glycerol, 50 nM Tris, 3% bromophenol blue, 2% beta -mercaptoethanol, pH 7.6), boiled for 5 min, then immediately placed on ice. Samples (25, 50, 75, or 100 µg) were loaded for electrophoretic separation of proteins. SDS-PAGE electrophoresis was performed by standard techniques, and proteins were transferred to a polyvinylidene difluoride microporous membrane.

After blotting, the membrane was immediately placed into blocking buffer [2% bovine serum albumin in wash buffer (10 mM Tris, 100 mM NaCl, 0.1% Tween 20, distilled H2O added to 1 liter)] on a shaking apparatus for 30 min at 37°C. The blocking buffer was discarded and replaced with new blocking buffer containing goat anti-bovine type IV collagen antibody (Southern Biotechnology) (1:250 dilution). The membrane was incubated with the primary antibody solution on a shaking apparatus for 30 min at 37°C. The membrane was next washed for 30 min with agitation. The membrane was then placed in 5% nonfat milk in wash buffer containing goat anti-mouse IgG conjugated to horseradish peroxidase (Sigma). The antibody conjugate was allowed to incubate for 30 min at 37°C with agitation. After washing, the membrane was treated with enhanced chemiluminescence reagent (Amersham Life Sciences, Arlington Heights, IL) according to the instructions of the manufacturer. Kodak X-Omat 4R film was exposed to the blot for 10 min. Bands were quantitated by laser densitometry. Human type IV collagen (Sigma) was used as a positive control in Western blotting experiments. Appropriate negative controls using irrelevant antibodies were also performed.

Statistics. For each individual experiment, the mean of replicate determinations in three individual wells was calculated. Values are means ± SE. Differences among groups were tested by analysis of variance. Where the F statistic was significant, comparisons between groups were performed with Student's two-tailed unpaired t-tests. Statistical significance was defined using an overall type I error at P <=  0.05.

    RESULTS
Top
Abstract
Introduction
Methods
Results
Discussion
References

We examined the effect of FCS on COL4A1 gene transcription in transfected murine mesangial cells grown in phenol-free RPMI 1640 media. FCS increased reporter gene activity in a dose-dependent fashion, achieving a nearly 50% increment with 20% FCS (148.4 ± 3.1 relative luciferase units, expressed as a percentage of control untreated cells; P < 0.001, n = 13) (Fig. 1). FCS (20%) also significantly increased total cellular protein (784 ± 61 vs. 477 ± 35 µg/well, P < 0.01). Estradiol reduced 20% FCS-stimulated COL4A1 gene transcription to a level no greater than that obtained in serum-free media [119.4 ± 8.1 (n = 5), P = NS, vs. 0% FCS] but failed to reverse the stimulatory effect of 20% FCS on total cellular protein (736 ± 89 vs. 784 ± 61 µg/well, P = NS).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of fetal calf serum (FCS) and estradiol on type IV collagen gene transcription as assessed by activity of a collagen IV/luciferase gene construct. FCS stimulated alpha 1 type IV collagen gene transcription in a dose-dependent manner. FCS-stimulated gene transcription was reversed by estradiol (10-7 M). Solid bars, fetal calf serum; hatched bars, fetal calf serum + estradiol. * P < 0.001 vs. 0% FCS.

PDGF (10 ng/ml) stimulated COL4A1 gene transcription by mesangial cells grown in the absence of serum (119.3 ± 3.6 relative luciferase units, P < 0.001 vs. control) (Fig. 2). PDGF-stimulated reporter gene transcription was reversed by neutralizing antibody to PDGF (119.3 ± 3.6 vs. 99.1 ± 2.1 relative luciferase units; P < 0.001, n = 3) or by neutralizing antibody to TGF-beta (119.3 ± 3.6 vs. 106.0 ± 6.2 relative luciferase units; P < 0.003, n = 3). Antibody alone (anti-PDGF or anti-TGF-beta ) and normal rabbit IgG had no effect on reporter gene transcription in cells grown in the absence of serum (100.0 ± 1.1, 104.6 ± 3.7, and 96.3 ± 2.1 relative luciferase units, respectively; P = NS vs. 0% FCS).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of anti-platelet-derived growth factor (PDGF) and anti-transforming growth factor-beta (TGF-beta ) neutralizing antibody on PDGF-stimulated collagen IV gene transcription. PDGF (10 ng/ml) stimulated alpha 1 type IV collagen gene transcription. PDGF-stimulated gene transcription was inhibited by either anti-PDGF or anti-TGF-beta neutralizing antibody (20 µg/ml). * P < 0.001 vs. control. 1 P < 0.001 vs. PDGF. 2 P < 0.003 vs. PDGF.

TGF-beta 1 (2 ng/ml) stimulated COL4A1 gene transcription by mesangial cells grown in serum-free media (156.0 ± 11.3 relative luciferase units; P < 0.001 vs. control, n = 5). Anti-TGF-beta neutralizing antibody reversed TGF-beta -stimulated reporter gene transcription (156.0 ± 11.3 vs. 106.6 ± 3.9 luciferase units; P < 0.001, n = 5). Antibody alone and normal rabbit IgG had no effect on reporter gene transcription in cells grown in the absence of serum (104.6 ± 3.7 and 96.3 ± 2.1, P = NS vs. 0% FCS).

Anti-TGF-beta neutralizing antibody inhibited the stimulatory effects of 20% FCS on reporter gene transcription by 37% [148.3 ± 4.1 (n = 9) vs. 127.1 ± 3.4 (n = 8) relative luciferase units; P < 0.005]. Anti-TGF-beta antibody had no significant effect on the increase in total cellular protein induced by FCS (854 ± 84 vs. 784 ± 61 µg/well, P = NS). Similarly, anti-PDGF neutralizing antibody inhibited the stimulatory effects of 20% FCS on reporter gene transcription [148.3 ± 4.1 (n = 9) vs. 136.7 ± 0.3 (n = 3) relative luciferase units, P < 0.002] (Fig. 3). However, anti-PDGF antibody had no significant effect on the increase in total cellular protein induced by 20% FCS (872 ± 49 vs. 784 ± 61 µg/well, P = NS). The inhibitory effect of combined treatment with anti-PDGF and anti-TGF-beta antibodies on collagen IV gene transcription was no greater than that of anti-TGF-beta antibody alone [129.5 ± 0.5 (n = 3) vs. 127.1 ± 3.4 (n = 8) relative luciferase units, P = NS]. Normal rabbit IgG had no effect on 20% FCS-stimulated COL4A1 gene transcription [159.2 ± 7.4 (n = 4) vs. 148.3 ± 4.1 (n = 9), P = NS] or on total cellular protein (736 ± 89 vs. 784 ± 61 µg/well, P = NS).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of anti-PDGF and anti-TGF-beta neutralizing antibody on 20% FCS-stimulated collagen IV gene transcription as assessed by activity of a collagen IV/luciferase gene construct. FCS-stimulated gene transcription was inhibited by either anti-TGF-beta or anti-PDGF neutralizing antibody (20 µg/ml). Effects of anti-TGF-beta and anti-PDGF antibodies were not additive. * P < 0.001 vs. 0% FCS. 1 P < 0.005 vs. 20% FCS. 2 P < 0.002 vs 20% FCS. 3 P < 0.001 vs. 20% FCS.

Estradiol inhibited the stimulatory effect of 20% FCS on COL4A1 gene transcription [148.4 ± 3.1 (n = 13) vs. 119.4 ± 8.1 (n = 5) relative luciferase units, P < 0.019] (Fig. 4). In the presence of estradiol, anti-TGF-beta antibody failed to further reduce COL4A1 gene transcription [119.4 ± 8.1 (n = 5) vs. 115.6 ± 9.8 (n = 3) relative luciferase units, P = NS] (Fig. 4).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of anti-TGF-beta neutralizing antibody and of estradiol on 20% FCS-stimulated collagen IV gene transcription. FCS-stimulated gene transcription was inhibited by either estradiol (10-7 M) or anti-TGF-beta antibody (20 µg/ml). Effects of estradiol and anti-TGF-beta antibody were not additive. * P < 0.001 vs. 0% FCS. 1 P < 0.019 vs. 20% FCS. 2 P < 0.005 vs. 20% FCS. 3 P < 0.005 vs. 20% FCS.

We measured type IV collagen protein by Western blotting to confirm that intact cells respond to serum and other agents in a manner analogous to the reporter gene construct. As shown in Fig. 5, type IV collagen protein was increased in 20% FCS-treated cells (323.8 ± 24.6%, expressed as % of control values, P < 0.001 vs. control). This increase was reversed by anti-TGF-beta antibody (128.8 ± 13.2%, P < 0.01 vs. 20% FCS) and by anti-PDGF antibody (132.6 ± 15.7%, P < 0.01 vs. 20% FCS). The rise in type IV collagen protein was also inhibited by estradiol (144.6 ± 20.4%, P < 0.01 vs. 20% FCS). Neither anti-TGF-beta antibody, anti-PDGF antibody, nor estradiol had any effect on type IV collagen protein in control cells.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 5.   Representative Western blot for type IV collagen in mesangial cells treated with control media (lane 1), estradiol (10-7 M) (lane 2), 20% FCS (lane 3), 20% FCS + anti-TGF-beta antibody (20 µg/ml) (lane 4), 20% FCS + anti-PDGF antibody (20 µg/ml) (lane 5), or 20% FCS + estradiol (10-7 M) (lane 6). Type IV collagen protein was increased in cells treated with 20% FCS. This effect was reversed by antibody to TGF-beta or PDGF and by estradiol. No effect on type IV collagen protein in control cells was observed after treatment with estradiol (lane 2) or anti-TGF-beta or anti-PDGF antibody (not shown).

    DISCUSSION
Top
Abstract
Introduction
Methods
Results
Discussion
References

The beneficial effect of female gender on the development and progression of atherosclerosis may reflect, in part, reduced accumulation of vascular wall extracellular matrix (35). In this regard, estrogen administration reduces collagen deposition in the aorta of hypertensive and hypercholesterolemic animals and reduces type I and type III collagen synthesis by vascular smooth muscle cells in vitro (28). Analogous to its effects on atherosclerosis, female gender has been associated with a slower rate of progression of renal disease (35). The accumulation of glomerular extracellular matrix after renal injury is a precursor to the development of glomerular obsolescence and progressive loss of renal function (23). The ability of estradiol to suppress type IV collagen synthesis by mesangial cells grown in serum-supplemented media may translate into reduced accumulation of collagen after glomerular injury in females (23).

FCS contains numerous growth factors, including PDGF and small quantities of TGF-beta (18, 26, 38). In addition, FCS stimulates mesangial cells to increase TGF-beta mRNA in a dose-dependent manner (18). This latter effect may be mediated by PDGF present in the serum (1, 2). It has been suggested that the stimulatory effect of FCS on the synthesis of several mesangial matrix components is mediated by the ability of PDGF present in serum to stimulate cellular synthesis of TGF-beta and initiate autocrine effects (21).

Numerous studies demonstrate autocrine and paracrine interactions between PDGF and TGF-beta . Recombinant human PDGF increases the steady-state level of TGF-beta mRNA and induces the release of TGF-beta protein from cultured human mesangial cells (2, 4). PDGF also increases TGF-beta mRNA and/or protein in rat kidney fibroblasts, murine macrophages, human articular chondrocytes, and human renal proximal tubular cells (20, 31, 39, 40). Consistent with the observation that PDGF stimulates TGF-beta synthesis, glucose-stimulated TGF-beta synthesis in human mesangial cells and renal proximal tubular cells is mediated through release of PDGF (11, 30). Anti-PDGF-beta antibody reverses the increase in TGF-beta 1 gene expression and protein synthesis induced by high glucose (11, 30). Also consistent with the observation that PDGF upregulates mesangial cell TGF-beta expression, the effects of PDGF on mesangial cell matrix protein synthesis are reversed by anti-TGF-beta antibody (27, 38). In contrast, a single study failed to find an effect of exogenous PDGF on TGF-beta mRNA levels in rat mesangial cells (18).

Addition of PDGF to human mesangial cells increases fibronectin and type III collagen synthesis by stimulating the intermediate production of TGF-beta (27, 38). The PDGF-stimulated increase in each of these matrix proteins is inhibited by the addition of a neutralizing antibody to TGF-beta (27, 38). Mesangial cells grown in media containing a high glucose concentration or exposed to advanced glycosylation end products show enhanced type III collagen production which is mediated, in part, by increased cellular production of PDGF (38). Most of the stimulatory effect of PDGF on type III collagen synthesis under these conditions is due to the intermediate production of TGF-beta (38). High glucose also induces a biphasic growth response in mesangial cells, with early growth stimulation mediated by PDGF and later growth inhibition mediated by PDGF induction of TGF-beta (11). In contrast to these observations, a single study failed to find a significant effect of anti-PDGF antibody on collagen IV mRNA in mesangial cells grown in 20% FCS (12).

In most studies, TGF-beta has been shown to increase the abundance of collagenase-sensitive protein and to stimulate types I and IV collagen synthesis in rat, murine, and human glomerular mesangial cells (8, 14, 25, 37, 42). This stimulation occurs at the transcriptional level, as reflected in an increase in mRNA levels in the absence of any increase in mRNA transcript stability (5, 14, 17, 37). In addition to its effect on collagen synthesis in rat and murine mesangial cells, TGF-beta induces cellular hypertrophy and increases total cellular protein normalized for cell number (5, 8, 25).

We have previously shown that estradiol reverses the stimulatory effect of TGF-beta on mesangial cell COL4A1 gene transcription, using a minigene construct (34). This observation, in addition to those summarized above, led us to hypothesize that serum stimulates mesangial cells to increase their synthesis of alpha 1 type IV collagen by increasing cellular production of TGF-beta and that the ability of estradiol to suppress the synthesis of alpha 1 type IV collagen by mesangial cells grown in serum-supplemented media may be mediated via antagonism of the actions of TGF-beta .

In the present study, we examined interactions between serum, PDGF, TGF-beta , estradiol, and COL4A1 gene transcription in murine mesangial cells. We found that PDGF-stimulated collagen IV gene transcription is inhibited by neutralizing antibody to TGF-beta , suggesting that increased cellular production of TGF-beta mediates, in part, the stimulatory effects of PDGF on COL4A1 gene transcription. We also found that FCS stimulated COL4A1 gene transcription in a dose-dependent manner. FCS-stimulated gene transcription was inhibited by neutralizing antibody to either PDGF or TGF-beta . The observation that the inhibitory effect of combined treatment with anti-PDGF and anti-TGF-beta antibodies on COL4A1 gene transcription were no greater than that of anti-TGF-beta antibody alone implies that these cytokines act through a common mechanism. Our data show that more than one-third of the increase in COL4A1 gene transcription induced by 20% FCS was mediated by PDGF-stimulated TGF-beta production. In contrast, serum-induced increases in total cellular protein content were not suppressed by anti-TGF-beta or anti-PDGF neutralizing antibody.

A 3.2-kb sequence in the first intron of the alpha 1 (IV) gene modulates the activity of the collagen IV promoter (29, 32). This sequence contains a motif with close homology to a serum response element found in the gene encoding the human 70-kDa heat shock protein (6). Nuclear extracts from Engelbreth-Holm-Swarm tumor cells or differentiated F9 cells show DNA footprints that cover the region containing the serum response element (6). Thus serum-induced binding of transcription factors to this motif may be responsible for the component of serum-stimulated COL4A1 gene transcription that is TGF-beta independent.

Although estradiol had no effect on COL4A1 gene transcription in cells grown in the absence of serum, estradiol suppressed FCS-stimulated gene transcription. Of note, the TGF-beta -mediated component of serum-stimulated collagen IV gene transcription is of sufficient magnitude to account for the suppressive effects of estradiol observed in serum-supplemented media. In the presence of estradiol, anti-TGF-beta antibody failed to further reduce FCS-stimulated COL4A1 gene transcription. These data suggest that FCS stimulates murine mesangial cell type IV collagen gene transcription, in part, by increasing cellular production of TGF-beta and that estradiol suppresses type IV collagen gene transcription by cells grown in serum-supplemented media by antagonizing the effects of TGF-beta .

The increase in type IV collagen protein observed in cells treated with 20% FCS exceeded the magnitude of stimulation of COL4A1 gene transcription induced by FCS. This discrepancy may reflect additional posttranscriptional events.

We have only studied transcription of the alpha 1 chain of type IV collagen. However, the peculiar arrangement of the alpha 1 and alpha 2 chains of type IV collagen (head-to-head on the same chromosome, sharing a common bidirectional promoter) implies some common control mechanism for both genes (7). Moreover, since both chains form a triple helix with two alpha 1 chains and one alpha 2 chain, there usually exists concordance of transcriptional regulation in a ratio of 2:1 (6).

The murine alpha 1 and alpha 2 type IV collagen genes are located on chromosome 13 in a head-to-head orientation separated by a common bidirectional promoter region spanning 130 base pairs (7). Kuncio et al. (22) have recently shown that the common promoter is sufficient to confer positive regulation by TGF-beta 1 in murine renal tubular cells. The common promoter contains binding sites for the transcription factor Sp1 (GGGCGG) but lacks an estrogen responsive element (7). Sp1 has been shown to mediate the effects of TGF-beta on the transcription of a number of genes, including the genes for alpha 1(I) and alpha 2(I) collagen and the cyclin-dependent kinase inhibitors p21 and p15INK4B (9, 15, 16, 24). In preliminary studies, we have shown that nuclear extracts from mesangial cells treated with TGF-beta show increased binding to an Sp1 site in the promoter of the type IV collagen gene and that estradiol reverses this enhanced binding (34). These observations are consistent with the hypothesis that Sp1 is involved in the regulation of collagen IV synthesis by TGF-beta and that estradiol reverses the stimulatory effects of TGF-beta on collagen IV synthesis via interactions with Sp1.

    FOOTNOTES

Address for reprint requests: J. Neugarten, Montefiore Medical Center, 111 E. 210 St., Bronx, NY 10467.

Received 18 March 1997; accepted in final form 18 September 1997.

    REFERENCES
Top
Abstract
Introduction
Methods
Results
Discussion
References

1.   Abboud, H. E., K. A. Walker, S. Snyder, and L. F. Bonewald. Regulation of transforming growth factor beta by platelet-derived growth factor in human mesangial cells (Abstract). Clin. Res. 39: 358, 1991.

2.   Abboud, H. E., A. J. Woodruff, S. P. Snyder, and L. F. Bonewald. Polypeptide growth factors regulate the production of latent transforming growth factor beta  in human mesangial cells (Abstract). J. Am. Soc. Nephrol. 2: 434, 1991.

3.   Ausubel, F., R. Brent, R. Kingston, D. Moore, and J. Seidman. Introduction of DNA into mammalian cells. In: Current Protocols in Molecular Biology, edited by J. Smith, and K. Strubel. New York: Wiley, 1990, p. 901-919.

4.   Barnes, J. L., K. A. Woodruff, S. P. Levine, and H. E. Abboud. Inhibition of mesangial cell proliferation by platelet factor 4. J. Am. Soc. Nephrol. 7: 991-998, 1996[Abstract].

5.   Border, W. A., S. Okuda, L. R. Languino, and E. Ruoslahti. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int. 37: 689-695, 1990[Medline].

6.   Burbelo, P. D., P. Klotman, L. Bruggeman, B. Clement, and Y. Yamada. Regulation of basemant membrane genes. CRC Crit. Rev. Eukaryotic Gene Expression 1: 1-10, 1990[Medline].

7.   Burbelo, P. D., G. R. Martin, and Y. Yamada. alpha 1(IV) and alpha 2(IV) collagen genes are regulated by a bidirectional promoter and a shared enhancer. Proc. Natl. Acad. Sci. USA 85: 9679-9682, 1988[Abstract/Free Full Text].

8.   Choi, M. E., E-G. Kim, Q. Huang, and B. J. Ballermann. Rat mesengial cell hypertrophy in response to transforming growth factor-beta 1. Kidney Int. 44: 948-958, 1993[Medline].

9.   Datto, M. B., Y. Yu, and X-F. Wang. Functional analysis of the transforming growth factor beta  responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270: 28623-28628, 1995[Abstract/Free Full Text].

10.   De Wet, J. R., K. V. Wood, M. de Luca, D. R. Helinski, and S. Subramani. Firefly luciferase gene structure and expression in mammalian cells. Mol. Cell. Biol. 7: 725-737, 1987[Abstract/Free Full Text].

11.   Di Paolo, S., L. Gesualdo, E. Ranieri, G. Grandaliano, and F. P Schena. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am. J. Pathol. 149: 2095-2106, 1996[Abstract].

12.   Doi, T., H. Vlassara, M. Kirstein, Y. Yamada, G. E. Striker, and L. J. Striker. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelelt-derived growth factor. Proc. Natl. Acad. Sci. USA 89: 2873-2877, 1992[Abstract/Free Full Text].

13.   Fumo, P., G. S. Kuncio, and F. N. Ziyadeh. PKC and high glucose stimulate collagen alpha 1(IV) transcriptional activity in a reporter mesangial cell line. Am. J. Physiol. 267 (Renal Fluid Electrolyte Physiol. 36): F632-F638, 1994[Abstract/Free Full Text].

14.   Hansch, G. M., C. Wagner, A. Burger, W. Dong, G. Staehler, and M. Stoeck. Matrix protein synthesis by glomerular mesangial cells in culture: effects of transforming growth factor beta  (TGF-beta ) and platelet-derived growth factor (PDGF) on fibronectin and collagen type IV mRNA. J. Cell. Physiol. 163: 451-457, 1995[Medline].

15.   Inagaki, Y., S. Truter, and F. Ramirez. Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J. Biol. Chem. 269: 14828-14834, 1994[Abstract/Free Full Text].

16.   Inagaki, Y., S. Truter, S. Tanaka, M. Di Liberto, and F. Ramirez. Overlapping pathways mediate the opposing actions of tumor necrosis factor-alpha and transforming growth factor-beta on alpha 2(I) collagen gene transcription. J. Biol. Chem. 270: 3353-3358, 1995[Abstract/Free Full Text].

17.   Ishimura, E., R. B. Sterzel, and M. Kashgarian. Effect of transforming growth factor (TGF)-beta on extracellular matrix (ECM) production by cultured rat mesangial cells (MCs) (Abstract). Kidney Int. 37: 197, 1990.

18.   Kaname, S., S. Uchida, E. Ogata, and K. Kurokawa. Autocrine secretion of transforming growth factor-beta in cultured rat mesangial cells. Kidney Int. 42: 1319-1321, 1992[Medline].

19.   Killen, P. D., P. D. Burbelo, G. R. Martin, and Y. Yamada. Characterization of the promoter for the alpha 1(IV) collagen gene. DNA sequences within the first intron enhance transcription. J. Biol. Chem. 263: 12310-12314, 1988[Abstract/Free Full Text].

20.   Kim, S-J., P. Angel, R. Lafyatis, K. Hattori, K. Y. Kim, M. B. Sporn, M. Karin, and A. B. Roberts. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10: 1492-1497, 1990[Abstract/Free Full Text].

21.   Kreisberg, J. I., R. A. Radnik, and S. H. Kreisberg. Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF-beta or PMA. Kidney Int. 50: 805-810, 1996[Medline].

22.   Kuncio, G. S., R. Alvarez, S. Li, P. D. Killen, and E. G. Neilson. Transforming growth factor-beta moldulation of the alpha 1(IV) collagen gene in murine proximal tubular cells. Am. J. Physiol. 271 (Renal Fluid Electrolyte Physiol. 40): F120-F125, 1996[Abstract/Free Full Text].

23.   Kwan, G., J. Neugarten, M. Sherman, Q. Ding, U. Fotadar, J. Lei, and S. Silbiger. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int. 50: 1173-1179, 1996[Medline].

24.   Li, J-M., M. A. Nichols, S. Chandrasekharan, Y. Xiong, and X-F. Wang. Transforming growth factor beta  activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J. Biol. Chem. 270: 26750-26753, 1995[Abstract/Free Full Text].

25.   MacKay, K., L. J. Striker, J. W. Stauffer, T. Doi, L. Y. Agodoa, and G. E. Striker. Transforming growth factor-beta . J. Clin. Invest. 83: 1160-1167, 1989.

26.   Masui, T., L. M. Wakefield, J. F. Lechner, M. A. LaVeck, M. B. Sporn, and C. C. Harris. Type beta  transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc. Natl. Acad. Sci. USA 83: 2438-2442, 1986[Abstract/Free Full Text].

27.   McKay, N. G., D. A. Power, A. M. MacLeod, and N. E. Haites. Increased fibronectin incorporation into extracellular matrix in response to platelet-derived growth factor is mediated by transforming growth factor beta. Exp. Nephrol. 3: 142, 1995[Medline].

28.   Neugarten, J., and S. Silbiger. Effects of sex hormones on mesangial cells. Am. J. Kidney Dis. 26: 147-151, 1995[Medline].

29.   Nishiyama, S., T. Taguchi, and S. Onosaka. Induction of zinc-thionein by estradiol and protective effects on inorganic mercury induced renal toxicity. Biochem. Pharmacol. 36: 3387-3391, 1987[Medline].

30.   Phillips, A. O., R. Steadman, N. Topley, and J. D. Williams. Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. Am. J. Pathol.. 147: 362-374, 1995[Abstract].

31.   Pierce, G. F., T. A. Mustoe, J. Lingelbach, V. R. Masakowski, P. Gramates, and T. F. Deuel. Transforming growth factor beta  reverses the glucocorticoid induced wound-healing deficit in rats: Possible regulation in macrophages by platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 86: 2229-2233, 1989[Abstract/Free Full Text].

32.   Schlondorff, D., W. Trizna, E. De Rosis, and S. K. Schutz. Effect of testosterone on compensatory renal hypertrophy in the rat. Endocrinology 101: 1670-1675, 1977[Abstract].

33.   Silbiger, S., S. Crowley, Z. Shan, M. Brownlee, J. Satriano, and D. Schlondorff. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 43: 853-864, 1993[Medline].

34.   Silbiger, S., J. Lei, F. N. Ziyadeh, and J. Neugarten. Estradiol reverses TGF-beta -1-stimulated type IV collagen synthesis in murine mesangial cells (Abstract). J. Am. Soc. Nephrol. 8: 527, 1997.

35.   Silbiger, S., and J. Neugarten. The impact of gender on the progression of chronic renal disease. Am. J. Kidney Dis. 25: 515-533, 1995[Medline].

36.   Southern, P. J., and P. Berg. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet. 1: 327-341, 1982[Medline].

37.   Suzuki, S., I. Ebihara, Y. Tomino, and H. Koide. Transcriptional activation of matrix genes by transforming growth factor beta 1 in mesangial cells. Exp. Nephrol 1: 229-237, 1993[Medline].

38.   Throckmorton, D. C., A. P. Brogden, B. Min, H. Rasmussen, and M. Kashgarian. PDGF and TGF-beta mediate collagen protion by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 48: 111-117, 1995[Medline].

39.   Van Obberghen-Schilling, E., N. S. Roche, K. C. Flanders, M. B. Sporn, and A. B. Roberts. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J. Biol. Chem. 263: 7741-7746, 1988[Abstract/Free Full Text].

40.   Villiger, P. M., and M. Lotz. Differential expression of TGF-beta isoforms by human articular chondrocytes in response to growth factors. J. Cell. Physiol. 151: 318-325, 1992[Medline].

41.   Wolf, G., U. Haberstroh, and E. G. Neilson. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am. J. Pathol. 140: 95-107, 1992[Abstract].

42.   Ziyadeh, F. N., K. Sharma, M. Ericksen, and G. Wolf. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta . J. Clin. Invest. 93: 536-542, 1994.


AJP Renal Physiol 274(2):F252-F258
0363-6127/98 $5.00 Copyright © 1998 the American Physiological Society




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lei, J.
Right arrow Articles by Neugarten, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lei, J.
Right arrow Articles by Neugarten, J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online